This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Clovis Oncology (CLVS) Soars: Stock Adds 6.6% in Session
by Zacks Equity Research
Clovis Oncology (CLVS) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now
by Zacks Equity Research
Hologic's (HOLX) GYN Surgical business boasts huge future prospects. Also, the recent commercial launch of MyoSure MANUAL device in the United States looks promising.
Orthofix (OFIX) Earnings & Revenues Beat Estimates in Q4
by Zacks Equity Research
Orthofix (OFIX) launches 20 products in 2018 and even schedules 17 more to be unveiled this year. Also, a strong full-year guidance bodes well for the company's better prospects.
Achillion Pharmaceuticals (ACHN) Soars: Stock Adds 15.4% in Session
by Zacks Equity Research
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares rise more than 15% on the day.
Masimo's SpHb Hemoglobin Monitoring Study Results Positive
by Zacks Equity Research
New study proves that Masimo's (MASI) noninvasive SpHb is more efficient in hemoglobin monitoring when compared to invasive LabHb.
Here's Why You Must Add Haemonetics (HAE) to Your Portfolio
by Zacks Equity Research
Haemonetics (HAE) delivers strong plasma revenues, driven by a robust performance in disposables and software in the United States. Also, the market seems upbeat about this new PCS platform.
Varian (VAR) Acquires Evinance to Boost Oncology Segment
by Zacks Equity Research
Varian Medical Systems (VAR) acquires Evinance to improve cancer care through CDS software. The company also expects to gain from flagship ARIA's recent certification.
Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 14.4% in Session
by Zacks Equity Research
Sangamo Therapeutics (SGMO) shares rose more than 14% in the last trading session, amid huge volumes.
Express Scripts, Walgreens Tie Up to Cut Specialty Drug Price
by Zacks Equity Research
Express Scripts (ESRX) expands group purchasing effort with Walgreens Boots Alliance to simplify supply chains and make specialty drugs affordable.
Cerner Partnering With Surescripts to Revamp EHR Platform
by Zacks Equity Research
Cerner (CERN) will introduce Surescripts' Real-Time Prescription Benefit functionality into "Cerner Millennium's" EHR platform to help clients curtail escalating healthcare costs.
Hologic Banks on Diagnostics, GYN Surgical Prospects Bright
by Zacks Equity Research
Hologic (HOLX) stays upbeat about GYN Surgical on the recent commercial launch of MyoSure MANUAL device in the United States.
Pharmacy Services Aid CVS Health, Aetna Deal an Upside Too
by Zacks Equity Research
CVS Health (CVS) is likely to earn $750 million from near-term synergies after the completion of Aetna acquisition deal.
Inogen (INGN) Gains on Diverse Product Line, Competition Rife
by Zacks Equity Research
Inogen (INGN) rides on POC growth. Existing market challenges likely to mar prospects.
Exactech (EXAC) Gets Acquired by TPG Capital, Goes Private
by Zacks Equity Research
TPG Capital acquires Exactech (EXAC) with a view to cash in on its resources and gain a foothold in the orthopedics market.
Abiomed's Extended FDA Nod for Impella Boosts Women Health
by Zacks Equity Research
Abiomed (ABMD) boosts cardiomyopathy treatment with the extended FDA nod for Impella. This parallelly bolsters women's cardiac treatment.
AmerisourceBergen (ABC) Gains on World Courier Unit Strength
by Zacks Equity Research
AmerisourceBergen's (ABC) World Courier business gets GDP designation.
Sanofi (SNY) Q4 Earnings Lag on Weak Diabetes/Vaccines Sales
by Zacks Equity Research
Sanofi misses estimates for both earnings and sales in the fourth quarter hurt by continued weakness in the Diabetes franchise and lower vaccine sales. Sanofi looks to return to growth in 2018.
4 Reasons Why You Should Buy Accuray (ARAY) Stock Right Now
by Zacks Equity Research
Accuray (ARAY) rides high on its Radixact platform and latest software overhaul.
Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B
by Zacks Equity Research
Sanofi (SNY) to acquire Ablynx for EUR 3.9 billion to expand its late stage pipeline and strengthen rare blood disorder growth platform.
Masimo (MASI) Receives FDA Approval for SedLine, Shares Up
by Zacks Equity Research
Masimo (MASI) to overhaul neurological diagnoses with its next generation SedLine brain function monitoring.
Iovance Biotherapeutics (IOVA) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) shares rose more than 5% in the last trading session, amid huge volumes.
Adverum Biotechnologies (ADVM) Jumps: Stock Rises 7.9%
by Zacks Equity Research
Adverum Biotechnologies (ADVM) was a big mover last session, as the company saw its shares nearly 8% on the day amid huge volumes.
Editas Medicine (EDIT) Surges: Stock Moves 13.2% Higher
by Zacks Equity Research
Editas Medicine (EDIT) was a big mover last session, as the company saw its shares rise more than 13% on the day amid huge volumes.
Quality Systems (QSII) Q3 Earnings in Line, Revenues Beat
by Zacks Equity Research
Quality Systems (QSII) benefits from solid bookings and acquisitions in Q3.
AngioDynamics Receives FDA Nod, to Treat Pancreatic Cancer
by Zacks Equity Research
AngioDynamics (ANGO) gets flagship NanoKnife designated with EAP.